BTIG analyst Mark Massaro initiated coverage of Caris Life Sciences (CAI) with a Buy rating and $38 price target Caris offers the first and only FDA-approved WES/WTS tissue-based assay, is now building greater interest in its newer liquid biopsy test and its biopharma offerings, and with time, will launch in MRD testing and in early cancer detection, the analyst tells investors in a research note. BTIG adds that its checks with medical oncologists unveiled that Caris is a high-quality lab provider that can find malignancies that other labs at times can miss, in part since Caris tests a patient’s full transcriptome.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences initiated with an Outperform at Wolfe Research
- Caris Life Sciences initiated with a Buy at Citi
- Caris Life Sciences initiated with a Buy at TD Cowen
- Strong Sales Growth and Strategic Market Expansion Drive Buy Rating for Caris Life Sciences
- Caris Life Sciences initiated with a Buy at Guggenheim